PCV8 EPROSARTAN VERSUS OTHERANGIOTENSIN-RECEPTOR BLOCKERS COMMONLY USED IN POLAND IN PATIENTS WITH HYPERTENSION-INDIRECT ANALYSIS  by Kaczor, M et al.
mean LDL-C reduction and difference in event rate between
statin and placebo arms in published outcomes studies (4S,
CARE, LIPID, HPS), was performed for major clinical endpoints.
A model was developed to estimate LDL-C reductions using
alternative baseline LDL-C values and the weighted mean differ-
ence (WMD) from the meta-analysis. These were combined with
results from regression analyses to calculate percentage reduction
in cardiovascular events and impact estimated for a population
of 100,000. The model was also run using the 95% conﬁdence
intervals from the meta-analysis. RESULTS: Meta-analysis
demonstrated a signiﬁcant reduction in LDL-C in favour of rosu-
vastatin 40 mg (WMD –5.26%, 95% CI: –6.08% to –4.43%;
p < 0.00001). There was no signiﬁcant heterogeneity identiﬁed in
the meta-analysis (p = 0.42) with low inconsistency in trial
results (I2 = 2.1%). Regression analyses showed good correla-
tion (R2 > 0.65) between LDL-C reduction and percentage dif-
ference in event rates for coronary death, major coronary event,
non-fatal myocardial infarction (MI) and revascularisations
(CABG and PCTA). Simulations using alternative LDL-C distri-
butions with means varying from 3.40–7.56 mmol/L generated
LDL-C reductions of 1.68–3.78 and 1.85–4.18 for rosuvastatin
20 mg and 40 mg, respectively. These values translated into the
following reductions depending on the mean of the distribution:
0.33%–0.74% coronary deaths; 0.72%–1.62% major coronary
events; 0.52%–1.17% non-fatal MIs; 0.59%–1.32% revasculari-
sation procedures. Based on a population of 100,000, the incre-
mental beneﬁt of rosuvastatin 40 mg over 20 mg resulted in the
prevention of 329–742 coronary deaths, 721–1,624 major coro-
nary events, 517–1,165 non-fatal MIs and 586–1,321 revascu-
larisation procedures. CONCLUSION: Rosuvastatin 40 mg
reduces LDL-C signiﬁcantly more than 20 mg. Modelled out-
comes suggest this may translate into substantially fewer
cardiovascular-related events.
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OBJECTIVES: With the lowering of the recommended choles-
terol levels in Europe, use of lipid lowering drugs has become a
more important clinical option. The study aim was to determine
total cholesterol levels by type of lipid lowering therapy in the
primary care setting in France, Italy and the UK. METHODS:
The study populations were identiﬁed from the THALES
(France, Italy) and The Health Improvement Network “THIN”
(UK) primary care databases. Patients were included if they
received a ﬁbrate or statin prescription in the ﬁrst 6 months of
2005 (index), had a prescription at least 6 months before index
and had a valid cholesterol record during the 12 months after
index. To account for differing cholesterol reporting habits,
analyses were restricted to general practitioners with cholesterol
reporting rate >50%. Multivariate linear regression was applied
to compare the effect of drug type on cholesterol level by country.
RESULTS: The rates of statin use were 71%, 88% and 97% for
France, Italy and the UK respectively. In France, the median
cholesterol was 5.2 mmol/L among statin users (n = 22674;
mean age = 65; male = 57%) compared to 5.3 mmol/L among
ﬁbrate users (n = 9283; age = 66; male = 46%). In Italy,
the median cholesterol was 5.2 mmol/L among statin users
(n = 4822; age = 67; male = 48%) compared to 5.4 mmol/L
among ﬁbrates users (n = 641; age = 65; male = 56%). In the
UK, median cholesterol was 4.4 mmol/L among statin users
(n = 113252; age = 67; male = 55%) compared to 5.1 mmol/L
among ﬁbrate users (n = 3626; age = 65; male = 49%). For each
country, statin therapy was associated (p < 0.001) with lower
median cholesterol level after controlling for age, gender, dia-
betes and coronary heart disease. CONCLUSION: The use of
statins in primary care was dominant in all countries studied,
although prescribing habits varied. Cholesterol levels were lower
among statin users than ﬁbrate users and this difference was
greatest in the UK.
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OBJECTIVES: To compare the clinical effectiveness of eprosa-
rtan and irbesartan, losartan, telmisartan and valsartan in
patients with hypertension. METHODS: The clinical effective-
ness analysis in accordance with the Cochrane Collaboration
guidelines were performed. In the absence (or lack of sufﬁcient
data) of RCT making head-to-head comparisons of eprosartan
vs other angiotensin-receptor blockers meta-analysis based on
an indirect comparison was performed, using placebo as the
common comparator (Bucher method). RESULTS: Eprosartan
vs losartan- Because of the lack of sufﬁcient data, indirect
analysis was performed. Compared drugs was comparable in
terms of efﬁcacy. In the safety analysis no signiﬁcant differences
were observed between groups except withdrawal due to
adverse events which was more common in losartan group OR
0.46 (95%CI: 0.23; 0.96). Eprosartan vs telmisartan- Indirect
analysis showed that there is now statistically signiﬁcantly dif-
ference in change systolic pressure. There was statistically sig-
niﬁcant difference between groups on favors telmisartan in
achieving clinical response OR 0.42 (95%CI: 0.23; 0.76).
Safety of both interventions was the same. Eprosartan vs val-
sartan or irbesartan: Analysis based on indirect evidence
showed no signiﬁcant differences between the groups in terms
of efﬁcacy (change in systolic and diastolic pressure, response
to treatment).The incidence of adverse events was similar in
compared groups. CONCLUSION: Analysis suggests that epro-
sartan has comparable efﬁcacy to losartan, valsartan, irbe-
sartan. Telmisartan is more effective compared with eprosartan
for treatment of patients with hypertension. Safety of interven-
tions is comparable. However, results based on indirect evi-
dence need to be viewed cautiously.
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OBJECTIVES: This study compares the differences in incidences
of hospitalisations for cardiovascular events between users of
selected statins. METHODS: New statin users between January
1, 2000 and September 30, 2005 were extracted from the
PHARMO database (population 3 million) and followed for
maximally two years after start of statin use, up to December 31,
2005. Incidences of hospitalisations for fatal and non-fatal car-
diovascular disease (CVD) in general (including ischemic heart
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